About Us
Salathé Capital is a structured credit investment manager whose main focus is in the asset-backed securities market. Senior Leadership has over 40 years of combined experience and 10+ years working together.
Bridging Two Worlds
Traditional fixed-income investing has long been constrained by a fundamental limitation: the trade-off between attractive returns and increased risk. At Salathé Capital, we saw an opportunity to break through this barrier by asking a simple but powerful question: What if we could bridge the gap between fixed-income and equity investing?
Our Innovation
The answer led us to develop a groundbreaking approach—fixed-income products that uniquely link equity returns to rated debt instruments. This innovation eliminates the traditional divide between asset classes, offering fixed-income investors access to equity-like returns while maintaining the structural characteristics they require.
Our hybrid methodology combines time-tested fundamental research with cutting-edge technology to optimize the risk-return profile of underlying assets. We don't just analyze opportunities; we engineer them.
Our Philosophy
We believe that exceptional outcomes in fixed income require three essential elements: relentless innovation, exceptional talent, and flawless execution. By bringing these together, we're not just participating in the evolution of fixed-income investing—we're leading it.
At Salathé Capital, we're transforming how investors think about the relationship between risk, return, and correlation in their portfolios.
David Sturgeon
Founder & CEO
Mr. David Sturgeon has 20+ years of experience across various asset management roles and industries. Over the course of his career, Mr. Sturgeon has managed structured product investment portfolios for a family office and a hedge fund before developing the CSN.
Mr. Sturgeon is the founder of Salathé Capital, an alternative asset management firm, where he oversees the day-to-day operations the firm. Prior to his role at Salathé Capital, LLC, Mr. Sturgeon was a portfolio manager for R&D Capital Partners, a hedge fund that focused on structured products. The goal of the investment strategy was to reduce downside risk while also allowing for participation in the upside of the equities and commodities markets. R&D Capital Partners was a finalist for S&P Cap IQ’s fixed income manager of the year award in 2014. https://www.prnewswire.com/news-releases/sp-capital-iq-new-legacy-group-and-opal-financial-group-inc-announce-finalists-for-the-third-annual-global-emerging-manager-awards-300045151.html
Prior to these roles, Mr. Sturgeon worked as a senior analyst for Capital Strategies Inc., a single-family office, where he was responsible for modeling and due diligence for structured products and fixed income. Prior to his role at Capital Strategies Inc., Mr. Sturgeon was an analyst at LandCo Equity Partners, a real estate investment firm where his responsibilities included financial modeling and deal structure modeling for real estate private equity transactions. Prior to LandCo, Mr. Sturgeon worked as an analyst at Arrowhead Investments where his duties included financial modeling and pitch book preparation, as well as meeting with investors and researching potential real estate private equity business opportunities.
Mr. Sturgeon earned a Masters of Science in Finance from The University of Denver. He is a graduate of the University of Northern Colorado, where he earned a BA in Management.
Dr. Richard Williams
Founding Investor & Senior Managing Partner
Biotechnology Investment Leader
Dr. Richard Williams brings over 35 years of experience investing in and developing biotechnology companies. He has helped launch 15 pre-public biotech firms, serving on their boards and assisting with management recruitment, business planning, and capital raising. His most successful investments include Amgen, IGEN (acquired by Roche), and Supergen (acquired by Otsuka Pharma).
Leadership Experience
Dr. Williams served as Managing Partner of Mara Venture Partners, an early-stage biotech venture capital fund with operations in Belgium and the US, for six years. He also advised the Vesalius Biocapital Fund in the Benelux region for eight years.
From 1996 to 2003, he was managing partner and chief analyst at an options trading firm that held three seats on the Philadelphia Stock Exchange. At ASM Resources, the venture capital arm of the American Society of Microbiology, he served in multiple leadership roles including director, acting CEO, and secretary-treasurer over six years.
Board Service and Community Impact
Dr. Williams dedicated 13 years to Beacon College in Florida, serving on the Board of Trustees from 2002 to 2015 and as Board Chairman for 10 years. Beacon College was the first accredited institution to award bachelor's degrees specifically to students with learning differences and autism spectrum disorders.
He also served 15 years on the American Society of Microbiology's Endowment Investment Committee, helping manage their $110 million fund until 2018.
Academic and Research Background
Before entering finance, Dr. Williams spent 20 years in academic research, teaching microbiology and infectious diseases at European universities and working with the World Health Organization in Africa. He has authored 85 peer-reviewed scientific publications.
Education
-
PhD and BA - University of California, Berkeley